Prescription Drug Abuse and Prevention

whitePaper | December 15, 2022

In today’s hypercompetitive pharmaceutical and life sciences (PLS) industry, strategic partnerships are more critical than ever. A smaller life sciences company may have relationships with hundreds of healthcare providers and healthcare organizations.

whitePaper | December 12, 2022

To improve outcomes for cancer patients and take advantage of the groundbreaking scientific and technological progress made in oncology prevention, diagnosis, therapy

whitePaper | April 1, 2021

Every year, the U.S. pharmaceutical industry develops a variety of new drugs that provide valuable medical benefits. Many of those drugs are expensive and contribute to rising health care costs for the private sector and the federal government. Policymakers have considered policies that would lower drug prices and reduce federal drug expenditures. Such policies would probably reduce the industry’s incentive to develop new drugs.

whitePaper | January 20, 2023

Understanding an antibody’s mechanism of action (MOA) is critical to its clinical success. Not only does MOA have a large impact on safety and efficacy.

whitePaper | November 18, 2022

Small molecule drug development has changed substantially in recent years. With the heightened focus on molecularly targeted therapies, small molecule active pharmaceutical ingredients (APIs).

whitePaper | December 15, 2022

Successful execution of clinical trials requires the orchestration of multiple moving parts, with everything from protocol design and patient visit schedules, to lab kits and biological samples needing to seamlessly line up to ensure on-time, on-budget delivery of high-quality data.